Post-transplant lymphoproliferative disorders in a cohort of liver-transplanted adult patients from a reference hospital in Bogotá, Colombia

Biomédica

View Publication Info
 
 
Field Value
 
Title Post-transplant lymphoproliferative disorders in a cohort of liver-transplanted adult patients from a reference hospital in Bogotá, Colombia
Desórdenes linfoproliferativos postrasplante en una cohorte de pacientes adultos con trasplante hepático atendidos en un hospital de referencia en Bogotá, Colombia
 
Creator Jurado, Leonardo F.
Gómez-Aldana, Andrés
Tapias, Mónica
Cáceres, Daniela
Vera, Alonso
López-Panqueva, Rocío del Pilar
Andrade, Rafael E.
 
Subject Desorden Linfoproliferativo Post-Trasplante
Linfoma
Trasplante Hepático
Colombia.
 
Description Introduction: The Post-Transplant Lifoproliferative Disorders are characterized by an uncontrolled pathological lymphoid proliferation as a consequence of transplant immunosuppression therapy.
Objective: This study characterizes clinical and pathologically the cases of PTLD in a cohort of liver - transplanted adult patients during a 15 years period at the Fundación Santa Fe de Bogota University Hospital.
Materials and methods: This was an observational retrospective study; looking for the PTLD cases diagnosed during the study period Liver-Transplatation Unit and Pathology Department databases were reviewed. Epidemiological, clinical and pathological information was collected and statistics analyses were performed.
Results: During the research period 572 patients were transplanted, the incidence of PTDL was 2.44%; 79% were man and the average age at the time of diagnosis was 62.5 years; 71% of the cases were diagnosed during the first year after the transplant was performed, and the same percentage of patients were VEB seropositive. The most frequent pathological phenotype was the monomorphic y the majority of tumors was identified in the hepatic hilum. The one-year survival was 50%.
Conclusion: The high proportion of early-presentation cases, and also the high frequency of Epstein-Barr virus seropositivity both in donors and receptors, called the attention. More studies are necessary in order to achieve a better knowledge of this condition in Colombia. This study represents the first PTLD clinic-pathological analysis in liver transplanted patients performed in Colombia to date.
Introducción. Los desórdenes linfoproliferativos post-trasplante se caracterizan por la proliferación descontrolada de linfocitos como consecuencia de la inmunosupresión administrada después del trasplante.
Objetivo. Caracterizar clínica y patológicamente los casos de PTLD en una cohorte de pacientes adultos con trasplante de hígado atendidos durante un periodo de 15 años en el Hospital Universitario Fundación Santa Fe de Bogotá.
Materiales y métodos. Estudio observacional retrospectivo. Se revisaron las bases de datos de la Unidad de Trasplante Hepático y del Departamento de Patología en busca de los casos de PTLD que se diagnosticaron durante el periodo de estudio. Se recolectó información epidemiológica, clínica y patológica y se adelantaron análisis de estadísticos.
Resultados. Durante el periodo de estudio hubo 572 pacientes con trasplante hepático, la incidencia de desórdenes linfoproliferativos fue de 2,44%, el 79% fueron hombres y la edad promedio al momento del diagnóstico fue de 62,5 años. El 71% de los casos se presentó durante los primeros 12 meses postrasplante y el mismo porcentaje eran seropositivos para VEB. El fenotipo patológico más frecuente fue el monomórfico y la mayoría de los tumores se identificaron en el hilio hepático. La supervivencia al año fue del 50%.
Conclusiones. Llamó la atención el alto porcentaje de casos de presentación temprana, así como la alta frecuencia de seropositividad para virus Epstein-Barr tanto en los donantes como en los receptores. Investigaciones más profundas deben ser adelantadas a fin de logran un mejor entendimiento de esta patología en el país. El presente corresponde al primer análisis clínico patológico de PTLD en pacientes con trasplante hepático adelantado en Colombia hasta la fecha.
 
Publisher Instituto Nacional de Salud
 
Date 2020-04-17
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://revistabiomedica.org/index.php/biomedica/article/view/4861
10.7705/biomedica.4861
 
Source Biomedica; Vol. 40 No. 3 (2020): Septiembre, publicación anticipada
Biomédica; Vol. 40 Núm. 3 (2020): Septiembre, publicación anticipada
2590-7379
0120-4157
 
Language spa
 
Relation https://revistabiomedica.org/index.php/biomedica/article/view/4861/4556
/*ref*/Dierickx D, Cardinaels N. Posttransplant lymphoproliferative disorders following liver transplantation: where are we now? World J Gastroenterol 2015; 21(39): 11034 – 43 2. Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 1968; 4: 746 – 8 3. Starzl TE. et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583 – 7 4. Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. Cancer Treat Res 2015; 165: 305 – 7 5. Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Prim 2016; 2: 1 – 20 6. Luskin, MR et al. The Impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant 2015; 15: 2665 – 73 7. Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant 2012; 12: 976 – 83 8. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222 – 30 9. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008; 14: 1588 – 97 10. Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58: 1824 - 35 11. de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D’Avola D, Belsue V, et al Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 2013; 19: 937- 44 12. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O’Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222 – 8 13. Lu BR, Park KT, Hurwitz M, Cox KL, Berquist WE. Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation. Transplant Proc 2013; 45: 301 – 4 14. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002; 236: 429 – 36 15. Mendizabal M, Marciano S, dos Santos Schraiber L, Zapata R, Quiros R, Zanotelli ML, et al. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience. Clin Transplant 2013: 27: E469–E477 16. Mumtaz K, Faisal N, Marquez M, Healey A, Lilly LB, Renner EL. Post-transplant lymphoproliferative disorder in liver transplant recipients: Characteristics, management and outcome from a single-centre experience with >1000 liver transplantations. Can J Gastroenterol Hepatol 2015; 29 (8): 417 – 22 17. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6: 1017-1024 18. Lo RC, Chan SC, Chan KL, Chiang AK, Lo CM, Ng I. Posttransplant lymphoproliferative disorders in liver transplant recipients:a clinicopathological study. J Clin Pathol. 2013; 66: 392-8 19. Trofe J, Buell JF, Beebe TM, Hanaway MJ, First MR, Alloway RR, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5, 775 – 80 20. Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6, 2735 – 42 21. Kinch A, Cavelier L, Bengtsson M, Baecklund E, Enblad G, Backlin C, et al. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation. Am J Transplant 2014; 14, 2838 – 45 22. Sanz J, Arango M, Senent L, Jarque I, Montesinos P, Sempere A, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 2014; 49: 397 – 402
 
Rights Derechos de autor 2020 Biomédica
https://creativecommons.org/licenses/by/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library